Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

INTRODUCTION: Discontinuation of tyrosine kinase inhibitor (TKI) treatment is emerging as the main therapy goal for Chronic Myeloid Leukemia (CML) patients. The DESTINY trial showed that TKI dose reduction prior to cessation can lead to an increased number of patients achieving sustained treatment f...

Descripción completa

Detalles Bibliográficos
Autores principales: Karg, Elena, Baldow, Christoph, Zerjatke, Thomas, Clark, Richard E., Roeder, Ingo, Fassoni, Artur C., Glauche, Ingmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769401/
https://www.ncbi.nlm.nih.gov/pubmed/36568156
http://dx.doi.org/10.3389/fonc.2022.1028871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769401/
https://www.ncbi.nlm.nih.gov/pubmed/36568156
http://dx.doi.org/10.3389/fonc.2022.1028871

Ejemplares similares